Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7A6I

Crystal Structure of EGFR-T790M/V948R in Complex with LDC8201

Summary for 7A6I
Entry DOI10.2210/pdb7a6i/pdb
DescriptorEpidermal growth factor receptor, SULFATE ION, ~{N}-[5-[4-chloranyl-2-[4-(4-methylpiperazin-1-yl)phenyl]-1~{H}-pyrrolo[2,3-b]pyridin-3-yl]-2-methyl-phenyl]propanamide, ... (4 entities in total)
Functional Keywordsegfr, t790m/v948r, exon20, covalent, transferase
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight38836.19
Authors
Niggenaber, J.,Mueller, M.P.,Rauh, D. (deposition date: 2020-08-25, release date: 2022-02-23, Last modification date: 2024-01-31)
Primary citationLategahn, J.,Tumbrink, H.L.,Schultz-Fademrecht, C.,Heimsoeth, A.,Werr, L.,Niggenaber, J.,Keul, M.,Parmaksiz, F.,Baumann, M.,Menninger, S.,Zent, E.,Landel, I.,Weisner, J.,Jeyakumar, K.,Heyden, L.,Russ, N.,Muller, F.,Lorenz, C.,Bragelmann, J.,Spille, I.,Grabe, T.,Muller, M.P.,Heuckmann, J.M.,Klebl, B.M.,Nussbaumer, P.,Sos, M.L.,Rauh, D.
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors.
J.Med.Chem., 65:6643-6655, 2022
Cited by
PubMed Abstract: Despite the clinical efficacy of epidermal growth factor receptor (EGFR) inhibitors, a subset of patients with non-small cell lung cancer displays insertion mutations in exon20 in EGFR and Her2 with limited treatment options. Here, we present the development and characterization of the novel covalent inhibitors LDC8201 and LDC0496 based on a 1-pyrrolo[2,3-]pyridine scaffold. They exhibited intense inhibitory potency toward EGFR and Her2 exon20 insertion mutations as well as selectivity over wild type EGFR and within the kinome. Complex crystal structures with the inhibitors and biochemical and cellular on-target activity document their favorable binding characteristics. Ultimately, we observed tumor shrinkage in mice engrafted with patient-derived EGFR-H773_V774insNPH mutant cells during treatment with LDC8201. Together, these results highlight the potential of covalent pyrrolopyridines as inhibitors to target exon20 insertion mutations.
PubMed: 35486541
DOI: 10.1021/acs.jmedchem.1c02080
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.4 Å)
Structure validation

227111

數據於2024-11-06公開中

PDB statisticsPDBj update infoContact PDBjnumon